196 related articles for article (PubMed ID: 8436176)
1. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.
Bolt S; Routledge E; Lloyd I; Chatenoud L; Pope H; Gorman SD; Clark M; Waldmann H
Eur J Immunol; 1993 Feb; 23(2):403-11. PubMed ID: 8436176
[TBL] [Abstract][Full Text] [Related]
2. The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody.
Routledge EG; Falconer ME; Pope H; Lloyd IS; Waldmann H
Transplantation; 1995 Oct; 60(8):847-53. PubMed ID: 7482746
[TBL] [Abstract][Full Text] [Related]
3. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
[TBL] [Abstract][Full Text] [Related]
4. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.
Cole MS; Anasetti C; Tso JY
J Immunol; 1997 Oct; 159(7):3613-21. PubMed ID: 9317161
[TBL] [Abstract][Full Text] [Related]
5. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity.
Alegre ML; Tso JY; Sattar HA; Smith J; Desalle F; Cole M; Bluestone JA
J Immunol; 1995 Aug; 155(3):1544-55. PubMed ID: 7636216
[TBL] [Abstract][Full Text] [Related]
6. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody.
Alegre ML; Collins AM; Pulito VL; Brosius RA; Olson WC; Zivin RA; Knowles R; Thistlethwaite JR; Jolliffe LK; Bluestone JA
J Immunol; 1992 Jun; 148(11):3461-8. PubMed ID: 1534096
[TBL] [Abstract][Full Text] [Related]
7. Structured to reduce the mitogenicity of anti-CD3 antibody based on computer-guided molecular design.
Lv M; Li Y; Yu M; Sun Y; Lin Z; Qiao C; Luo Q; Gu X; Huang Y; Feng J; Shen B
Int J Biochem Cell Biol; 2007; 39(6):1142-55. PubMed ID: 17446118
[TBL] [Abstract][Full Text] [Related]
8. Helper effector function of human T cells stimulated by anti-CD3 mAb can be enhanced by co-stimulatory signals and is partially dependent on CD40-CD40 ligand interaction.
Kwekkeboom J; de Rijk D; Kasran A; Barcy S; de Groot C; de Boer M
Eur J Immunol; 1994 Mar; 24(3):508-17. PubMed ID: 7510232
[TBL] [Abstract][Full Text] [Related]
9. Characterization of IgG FcR-mediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3.
Parren PW; Warmerdam PA; Boeije LC; Capel PJ; van de Winkel JG; Aarden LA
J Immunol; 1992 Feb; 148(3):695-701. PubMed ID: 1530954
[TBL] [Abstract][Full Text] [Related]
10. Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems.
Van Lier RA; Boot JH; De Groot ER; Aarden LA
Eur J Immunol; 1987 Nov; 17(11):1599-604. PubMed ID: 2960543
[TBL] [Abstract][Full Text] [Related]
11. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects.
Vossen AC; Tibbe GJ; Kroos MJ; van de Winkel JG; Benner R; Savelkoul HF
Eur J Immunol; 1995 Jun; 25(6):1492-6. PubMed ID: 7614975
[TBL] [Abstract][Full Text] [Related]
12. Human retinal pigment epithelial cell interleukin-8 and monocyte chemotactic protein-1 modulation by T-lymphocyte products.
Elner SG; Elner VM; Bian ZM; Lukacs NW; Kurtz RM; Strieter RM; Kunkel SL
Invest Ophthalmol Vis Sci; 1997 Feb; 38(2):446-55. PubMed ID: 9040478
[TBL] [Abstract][Full Text] [Related]
13. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.
Alegre ML; Peterson LJ; Xu D; Sattar HA; Jeyarajah DR; Kowalkowski K; Thistlethwaite JR; Zivin RA; Jolliffe L; Bluestone JA
Transplantation; 1994 Jun; 57(11):1537-43. PubMed ID: 8009586
[TBL] [Abstract][Full Text] [Related]
14. Functional studies with anti-CD3 heavy chain isotype switch-variant monoclonal antibodies. Accessory cell-independent induction of interleukin 2 responsiveness in T cells by epsilon-anti-CD3.
van Lier RA; Boot JH; Verhoeven AJ; de Groot ER; Brouwer M; Aarden LA
J Immunol; 1987 Nov; 139(9):2873-9. PubMed ID: 3117878
[TBL] [Abstract][Full Text] [Related]
15. Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions.
Li B; Wang H; Dai J; Ji J; Qian W; Zhang D; Hou S; Guo Y
Immunology; 2005 Dec; 116(4):487-98. PubMed ID: 16313362
[TBL] [Abstract][Full Text] [Related]
16. Contrasting in vivo effects on T helper cell functions induced by mitogenic (intact) versus nonmitogenic (F(ab')2) anti-CD3 monoclonal antibody.
Sawchuk SS; Gates R; Hirsch R
Transplantation; 1995 Dec; 60(11):1331-7. PubMed ID: 8525530
[TBL] [Abstract][Full Text] [Related]
17. In vivo administration of anti-CD3 monoclonal antibody can activate immune responses thus preventing malignant tumor growth.
Hirsch R; Ellenhorn JD; Bluestone JA
Princess Takamatsu Symp; 1988; 19():237-43. PubMed ID: 2978618
[TBL] [Abstract][Full Text] [Related]
18. Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation.
Zhu Z; Carter P
J Immunol; 1995 Aug; 155(4):1903-10. PubMed ID: 7636241
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive properties of anti-CD3 single-chain Fv and diabody.
Le Gall F; Reusch U; Moldenhauer G; Little M; Kipriyanov SM
J Immunol Methods; 2004 Feb; 285(1):111-27. PubMed ID: 14871540
[TBL] [Abstract][Full Text] [Related]
20. Cascade modulation by anti-tumor necrosis factor monoclonal antibody of interferon-gamma, interleukin 3 and interleukin 6 release after triggering of the CD3/T cell receptor activation pathway.
Ferran C; Dy M; Sheehan K; Schreiber R; Grau G; Bluestone J; Bach JF; Chatenoud L
Eur J Immunol; 1991 Oct; 21(10):2349-53. PubMed ID: 1833202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
